Short radiation followed by chemo and targeted therapy for advanced rectal cancer
Part of Cancer, Digestive system clinical trials.
This trial tests a short course of radiation followed by chemotherapy and targeted drugs for people with rectal cancer that has spread and cannot be removed with surgery. It aims to see if this combination can shrink tumors and improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have rectal cancer that has not been treated before with surgery, radiation, chemo, targeted therapy, or immunotherapy.
- Your cancer must have spread to other parts of the body and cannot be surgically removed.
- You must be between 18 and 75 years old.
- You must be in generally good health with no serious heart, lung, liver, kidney, or blood problems.
- You must be willing to provide a tumor tissue sample for genetic testing.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding radiation therapy to a combination of chemotherapy (CAPOX) and an immunotherapy drug (PD-1 antibody) is more effective than the combination alone for people with locally advanced rectal cancer that is MSS (microsatellite stable) or pMMR. It aims to improve outcomes for patients with high-risk features.
This trial tests a combination of brief radiation therapy, two chemotherapy drugs (nal-IRI and capecitabine), and an immunotherapy drug (camrelizumab) for locally advanced rectal cancer. The goal is to shrink the tumor and improve outcomes before surgery.
This trial tests a new combination for rectal cancer that hasn't spread far: a short course of radiation followed by two drugs (AK112 and CAPOX). The goal is to shrink the tumor before surgery and possibly avoid more aggressive treatments.
This trial tests a combination of short-course radiation, chemotherapy (CapeOx), and an immunotherapy drug (PD-1 inhibitor) for people with early-stage rectal cancer who have had a local excision but are at high risk of the cancer coming back. The goal is to avoid more extensive surgery while still effectively treating the cancer.
This trial tests a new combination of treatments before surgery for locally advanced rectal cancer. You would receive short-course radiation, then an immunotherapy drug (camrelizumab) plus a PARP inhibitor (fluzoparib) and chemotherapy, to shrink the tumor and make surgery more successful.
This trial tests a new approach for people with locally advanced rectal cancer that has high-risk features. It combines short-course radiation with chemotherapy (CapeOX) and the immunotherapy drug toripalimab, with or without another drug called surufatinib, before surgery. The goal is to see if adding these drugs helps shrink the tumor and improve outcomes.
Hear when a new Unresectable Metastatic Rectal Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.